Marksans Pharma Board of Directors

Get the latest insights into the leadership at Marksans Pharma. Learn about the experienced professionals guiding the company's strategy and governance.

NamePosition
Mr. Mark Saldanha Chairman & Managing Director
Mrs. Sandra Saldanha Whole Time Director
Mr. Varddhman V Jain Whole Time Director
Dr. Sunny Sharma Non Executive Director
Mr. Srinivas Mishra Independent Director
Mr. Digant Mahesh Parikh Independent Director
Mr. Abhinna Sundar Mohanty Independent Director
Mrs. Shailaja Vardhan Independent Director

Marksans Pharma Share price

MARKSANS

171.58

1.44 (-0.83%)
NSE
BSE
Last updated on 4 Sep, 2025 | 15:59 IST
BUYSELL
Today's High

177.29

Today's Low

169.92

52 Week Low

165.52

52 Week High

358.70

The current prices are delayed, login to your account for live prices

Marksans Pharma FAQs

The board at Marksans Pharma consists of experienced professionals, including Mr. Mark Saldanha , Mrs. Sandra Saldanha , and others, overseeing the company’s strategic and corporate governance.

Directors at Marksans Pharma are typically nominated by the Nomination and Remuneration Committee and approved by shareholders, adhering to regulatory and governance standards. While this is the standard procedure, the exact process may differ depending on the company’s internal policies and governance framework.

As of the latest update, Mr. Mark Saldanha is the current chairman at Marksans Pharma.

Executive directors at Marksans Pharma are involved in day-to-day operations, while non-executive directors, including independents, provide oversight and strategic input. While this distinction is generally followed, the specific responsibilities of executive and non-executive directors may vary based on the company’s organisational structure and governance practices.

Yes, Marksans Pharma adheres to all applicable SEBI and Companies Act provisions related to board structure, diversity, and independence.

At Marksans Pharma, board members usually serve fixed terms as outlined in the company’s charter or governance policy, commonly ranging between three to five years, with the possibility of renewal based on performance, shareholder approval, and regulatory norms.